Table 2.
Treatment patterns
| First-line cohort (all) | First-line cohort (sorafenib) | Second-line cohort (all) | ||||
|---|---|---|---|---|---|---|
| N = 1459 | N = 1125 | N = 163 | ||||
| Months to treatment start (mean, SD) | 5.24 | 8.93 | 4.17 | 7.02 | 3.06 | 5.39 |
| Months to start (median) | 1.63 | 1.43 | 1.07 | |||
| Index therapya,b (N, %) | ||||||
| Systemic chemotherapy | 181 | 12.4% | 1 | 0.1% | 80 | 49.1% |
| Targeted therapies without sorafenib | 165 | 11.3% | 0 | 0.0% | 70 | 42.9% |
| Immunotherapy | 1 | 0.1% | 0 | 0.0% | 4 | 2.5% |
| Sorafenib | 1125 | 77.1% | 1125 | 100.0% | 15 | 9.2% |
| Reason for termination (N, %) | ||||||
| Discontinuation | 609 | 41.7% | 451 | 40.1% | 70 | 42.9% |
| Switching | 81 | 5.6% | 54 | 4.8% | 17 | 10.4% |
| Augmentation | 29 | 2.0% | 15 | 1.3% | 8 | 4.9% |
| Death | 190 | 13.0% | 169 | 15.0% | 12 | 7.4% |
| End of enrollment | 515 | 35.3% | 421 | 37.4% | 44 | 27.0% |
| End of study | 35 | 2.4% | 15 | 1.3% | 12 | 7.4% |
| Duration of therapy, months (mean, SD) | 5.06 | 5.98 | 4.90 | 5.63 | 5.13 | 7.29 |
| Duration of therapy, months (median) | 3.03 | 3.00 | 3.03 | |||
| Duration of 2L sorafenib, months (mean, SD) | 6.82 | 4.06 | ||||
| Duration of 2L sorafenib, months (median) | 7.47 | |||||
2L, second line; SD, standard deviation
aPatients can receive more than one type of medication on the index date
bSee Online Resource Material 1 for a full list of therapies